Berzosertib hydrochloride (Synonyms: VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride) |
Catalog No.GC79103
One-Click Copy Product Info
|
Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1428935-04-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, Berzosertib (60 mg/kg; p.o.; daily; 10 days; 1 h before 2 Gy local tumor irradiation) hydrochloride acts synergistically with daily 2 Gy local radiation to delay subcutaneous NSCLC brain metastasis PDX tumor growth in mice[2]. Berzosertib (60 mg/kg; p.o.; daily; 5 days; 1 h before 2.5 Gy whole brain irradiation) hydrochloride combined with daily 2.5 Gy whole brain irradiation significantly improves median overall survival and reduces intracranial tumor growth in mouse NSCLC brain metastasis xenograft model[2]. Berzosertib (60 mg/kg; i.g.; 2 h before Gy IR, then daily for 3 days) hydrochloride produces antitumor efficacy in mouse MC38 and CT26 models, when combined with 5 Gy irradiation and anti-PD-L1[4].
In Vitro, Berzosertib (0.031-1 µM; 72 h) hydrochloride reduces cell viability in Cal-27 and FaDu HNSCC cell lines with IC50 values of 0.285 µM and 0.252 µM, respectively[1]. Berzosertib (0.125-0.5 µM; 24-48 h) hydrochloride inhibits migration in Cal-27 and in FaDu HNSCC cells[1]. Berzosertib (0.25-0.5 µM; 48 h) hydrochloride induces apoptosis in Cal-27 and FaDu cells[1]. Berzosertib (48-72 h) hydrochloride inhibits proliferation of A549, NCI-H226, and NCI-H520 cells with IC50 values in the 1-4 μM range[2]. Berzosertib (40-80 nM; 1 h) hydrochloride enhances radiosensitivity of A549, NCI-H226, and NCI-H520 NSCLC cell lines[2]. Berzosertib (40 nM; 1 h) hydrochloride inhibits radiation-induced ATR (Thr1989) phosphorylation in A549, NCI-H226, and NCI-H520 NSCLC cell lines without affecting ATM (Ser1981) activation[2]. Berzosertib (40 nM; 1 h) hydrochloride abrogates the radiation-induced G2/M cell cycle checkpoint in A549 NSCLC cells, shifting cells into G1 phase[2]. Berzosertib (40-80 nM; 1 h) hydrochloride enhances radiation-induced apoptosis in A549 NSCLC cells when combined with 10 Gy, but not 2 Gy, irradiation[2]. Berzosertib (40 nM; 1 h) hydrochloride inhibits DNA double-strand break repair in A549 cells[2]. Berzosertib (1 µM; 2 h) hydrochloride impairs irradiation-induced G2/M checkpoint initiation and maintenance in HCT116 and CT26 cells, promoting mitotic entry after DNA damage[4]. Berzosertib (1 µM; 2 h) hydrochloride combined with 5 Gy irradiation increases micronuclei formation and cytosolic dsDNA levels in HCT116 and CT26 colorectal cancer cell lines[4]. Berzosertib (1 µM; 2 h) hydrochloride combined with 5 Gy irradiation robustly activates the canonical cGAS-STING-pTBK1/pIRF3 pathway, and upregulates expression of interferon-stimulated genes CXCL10, CCL5, and IFNB in HCT116, SW480, CT26, and MC38 cells[4]. Berzosertib (1 µM; 2 h) hydrochloride combined with 5 Gy irradiation inhibits the recruitment of SHP1 to the TRAF6/STING complex in HCT116 cells, enhancing TRAF6-STING interaction[4].
References:
[1]. Schnoell J, et al. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines. Invest New Drugs. 2023;41(6):842-850.
[2]. Baschnagel AM, et al. ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. Mol Cancer Ther. 2021;20(11):2129-2139.
[3]. Fokas E, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3(12):e441. Published 2012 Dec 6.
[4]. Liu C, et al. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun (Lond). 2023;43(4):435-454.
[5]. Gorainow N, et al. Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy. Cell Death Dis. 2026;17(1):331. Published 2026 Mar 20.
[6]. Kurmasheva RT, et al. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2018;65(2):10.1002/pbc.26825.
| Cas No. | 1428935-04-9 | SDF | |
| Synonyms | VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride | ||
| Formula | C24H26ClN5O3S | M.Wt | 500.01 |
| Solubility | Storage | Store at 4°C, away from moisture | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2 mL | 9.9998 mL | 19.9996 mL |
| 5 mM | 400 μL | 2 mL | 3.9999 mL |
| 10 mM | 200 μL | 1 mL | 2 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)